health
Teclistamab outperforms lenalidomide in high-risk smoldering myeloma
In a randomized phase 2 trial, teclistamab produced deeper responses and longer progression-free survival than lenalidomide-dexamethasone in people with high-risk smoldering multiple myeloma. The study found high rates of complete response and minimal residual disease negativity after fixed-duration treatment.